AzurRx BioPharma Initiates European Arm of Phase 2b OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis

NEXT STORY
TRACON Pharmaceuticals Announces FDA Clearance of ENVASARC Pivotal Trial
PREV STORY
The World’s Pharmaceutical Drug Delivery Industry, 2025 – Growth in the Biologics Market is Driving Opportunities
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Virion Therapeutics, LLC Announces the Appointment of M. Michelle Berrey, M.D., M.P.H. and Williamson Bradford, M.D., Ph.D. to Its Board of Directors

author_avatar
NASDAQ Market News

Metacrine Appoints Pharmaceutical Business and R&D Executive, Preston Klassen, M.D., MHS, as President and Chief Executive Officer

author_avatar
NASDAQ Market News

Five Prime Therapeutics Presents Poster on FGFR2b Expression and Immune Signature in Urothelial Cancer at the Society for Immunotherapy of Cancer 32nd Annual Meeting

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), ...

author_avatar
NASDAQ Market News